- Home
- ECBK vs CGEN Comparison
ECBK vs CGEN Comparison
Compare ECBK & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ECBK
- CGEN
- Stock Information
- Founded
- ECBK 1919
- CGEN 1993
- Country
- ECBK United States
- CGEN Israel
- Employees
- ECBK N/A
- CGEN N/A
- Industry
- ECBK Banks
- CGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ECBK Finance
- CGEN Health Care
- Exchange
- ECBK Nasdaq
- CGEN Nasdaq
- Market Cap
- ECBK 151.0M
- CGEN 125.3M
- IPO Year
- ECBK N/A
- CGEN 2000
- Fundamental
- Price
- ECBK $15.48
- CGEN $1.75
- Analyst Decision
- ECBK
- CGEN
- Analyst Count
- ECBK 0
- CGEN 0
- Target Price
- ECBK N/A
- CGEN N/A
- AVG Volume (30 Days)
- ECBK 11.6K
- CGEN 377.9K
- Earning Date
- ECBK 10-23-2025
- CGEN 11-11-2025
- Dividend Yield
- ECBK N/A
- CGEN N/A
- EPS Growth
- ECBK 52.06
- CGEN N/A
- EPS
- ECBK 0.64
- CGEN N/A
- Revenue
- ECBK $27,795,000.00
- CGEN $22,144,000.00
- Revenue This Year
- ECBK N/A
- CGEN N/A
- Revenue Next Year
- ECBK N/A
- CGEN $208.08
- P/E Ratio
- ECBK $24.51
- CGEN N/A
- Revenue Growth
- ECBK 12.29
- CGEN N/A
- 52 Week Low
- ECBK $12.56
- CGEN $1.13
- 52 Week High
- ECBK $17.33
- CGEN $2.66
- Technical
- Relative Strength Index (RSI)
- ECBK 38.36
- CGEN 66.91
- Support Level
- ECBK $15.66
- CGEN $1.30
- Resistance Level
- ECBK $16.47
- CGEN $1.82
- Average True Range (ATR)
- ECBK 0.22
- CGEN 0.11
- MACD
- ECBK -0.04
- CGEN 0.05
- Stochastic Oscillator
- ECBK 14.59
- CGEN 85.32
About ECBK ECB Bancorp Inc.
ECB Bancorp Inc operates as a bank holding company of Everett Co-operative Bank. The firm through its subsidiary engages in business consisting of taking deposits from the general public and investing those deposits, together with funds generated from operations, in one- to four-family residential real estate loans, commercial real estate, and multifamily real estate loans, construction and land loans and home equity lines of credit.
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.